NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy

NCT03333655

CompletedPhase 4

Sponsor: Hoffmann-La Roche

Conditions: Neoplasms

Interventions: Biopsy

Countries: United States, France, South Korea, Spain, United Kingdom

The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CPI treatment of metastatic cancer or hematologic malignancies.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Response assessment of complete response (CR), partial response (PR), or long-term stable disease (SD) for \>6 months with a cancer immunotherapy treatment for metastatic cancer or hematologic malignancies either through a marketed CPI or through participation in a Roche/Genentech CPI clinical trial.
* Availability of tissue sample.

Exclusion Criteria:

* Pregnant, lactating, or intending to become pregnant during the study.
* Participants receiving CPI treatment as part of a non-Roche/Genentech clinical trial.

Locations (11)

San Francisco, California, United States
Boston, Massachusetts, United States
St Louis, Missouri, United States
New York, New York, United States
Arrington, Tennessee, United States
Toulouse, France
Seoul, South Korea
Seoul, South Korea
Pamplona, Navarre, Spain
Barcelona, Spain
London, United Kingdom